Barclays analyst Balaji Prasad lowered the firm’s price target on Ligand Pharmaceuticals to $110 from $120 and keeps an Overweight rating on the shares ahead of the Q2 results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LGND: